Claudin 18.2 expression in digestive neuroendocrine neoplasms: a clinicopathological study

• Published in: Journal of endocrinological investigation 2024-05, Vol.47 (5), p.1251-1260
• Main Authors: Jiang, K., Cao, F., Yin, L., Hu, Y., Zhao, X., Huang, X., Ma, X., Li, J., Lu, M., Sun, Y.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - analysis; Biomarkers, Tumor - metabolism; Carcinoma, Neuroendocrine - metabolism; Carcinoma, Neuroendocrine - pathology; Claudins - analysis; Claudins - metabolism; Digestive System Neoplasms - metabolism; Digestive System Neoplasms - pathology; Endocrinology; Female; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Metabolic Diseases; Middle Aged; Neuroendocrine tumors; Neuroendocrine Tumors - metabolism; Neuroendocrine Tumors - pathology; Original Article; Pancreas; Prognosis; Retrospective Studies; Tumors
• ISSN: 1720-8386; 0391-4097; 1720-8386
• DOI: 10.1007/s40618-023-02245-7

Background Claudin 18.2-targeted therapy has shown significant efficacy in treating claudin 18.2-positive cancers. However, limited systematic studies have investigated characteristics of claudin 18.2 expression in neuroendocrine neoplasms (NENs). Methods Data and specimens from 403 cases of digestive NENs were retrospectively collected, and claudin 18.2 expression was detected using immunochemical staining. Results Claudin 18.2 was positive in 19.6% (79/403) of the digestive NENs. The highest positive rate of claudin 18.2 was observed in gastric NENs (72/259, 27.8%), accounting for 91.1% (72/79) of all positive cases. The positivity rate was significantly higher in gastric NENs compared to pancreatic (2/78, 2.6%) or colorectal NENs (2/38, 5.3%; p